Saturday 30 June 2012

Statrol Ophthalmic Solution





Dosage Form: ophthalmic solution

DESCRIPTION


STATROL® (Neomycin and Polymyxin B Sulfates Ophthalmic Solution, USP) is a sterile ophthalmic drug combining two antibacterials in solution form.


Each mL of solution contains: Active: Neomycin Sulfate equivalent to 3.5 mg Neomycin base, Polymyxin B Sulfate equal to 16,250 polymyxin B units.


Preservative: Benzalkonium Chloride .004%. Vehicle: 0.5% Hydroxypropyl Methylcellulose 2910. Inactive: Boric Acid, Sodium Chloride, Hydrochloric Acid and/or Sodium Hydroxide (to adjust pH), Purified Water. DM-02



CLINICAL PHARMACOLOGY


The anti-infective components in Statrol Ophthalmic Solution provide action against specific organisms susceptible to them. Polymyxin B Sulfate and Neomycin Sulfate are active in vitro against Staphylococcus aureus, Escherichia coli, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa. This product does not provide adequate coverage against: Serratia marcescens, Streptococci, including Streptococcus pneumoniae.



INDICATIONS AND USAGE


STRATOL Ophthalmic Solution is indicated in the topical treatment of infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis, and keratoconjunctivitis, blepharitis and blepharoconjunctivitis, acute meibomianitis and dacryocystitis.



CONTRAINDICATIONS


Epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, and many other viral diseases of the cornea and conjunctiva. Mycobacterial infection of the eye. Fungal diseases of ocular structures. Hypersensitivity to a component of the medication.



WARNINGS


NOT FOR INJECTION INTO THE EYE. Should a sensitivity reaction occur, discontinue use. Neomycin Sulfate may cause cutaneous sensitization. Remove contact lenses before using.



PRECAUTIONS



General


As with other antibiotic preparations, prolonged use may result in overgrowth of nonsusceptible organisms, including fungi. If superinfection occurs, appropriate measures should be initiated. Whenever clinical judgment dictates; the patient should be examined with the aid of magnification, such as slit lamp biomicroscopy, and, where appropriate, corneal staining.



Information for patients


This product is sterile when packaged. To prevent contamination, care should be taken to avoid touching the bottle tip to eyelids or to any other surface. The use of this bottle by more than one person may spread infection. Keep bottle tightly closed when not in use. Keep out of the reach of children.



Carcinogenesis, Mutagenesis, Impairment of Fertility


Long-term studies in animals to evaluate carcinogenic or mutagenic potential have not been conducted with Polymyxin B Sulfate. Treatment of cultured human lymphocytes in-vitro with neomycin increased the frequency of chromosome aberrations at the highest concentrations (80 µg/mL) tested; however, the effects of neomycin on carcinogenesis and mutagenesis in humans are unknown.


Polymyxin B Sulfate has been reported to impair the motility of equine sperm, but its effects on male or female fertility are unknown.



Pregnancy


Teratogenic Effects

Pregnancy Category C. Animal reproduction studies have not been conducted with STATROL® (Neomycin and Polymyxin B Sulfates Ophthalmic Solution, USP). It is also not known whether Neomycin Sulfate and/or Polymyxin B Sulfate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Statrol Ophthalmic Solution should be given to a pregnant woman only if clearly needed.



Nursing Mothers


It is not known whether these drugs are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Statrol Ophthalmic Solution is administered to a nursing mother.



ADVERSE REACTIONS


Adverse reactions have occurred with the anti-infective components. Exact incidence figures are not available since no denominator of treated patients is available. Reactions occurring most often from the presence of the anti-infective ingredients are allergic sensitizations. (SEE WARNINGS.)



DOSAGE AND ADMINISTRATION


Instill one or two drops in the lower conjunctival sac(s) three or more times daily as required.



HOW SUPPLIED


STATROL (Neomycin and Polymyxin B Sulfates Ophthalmic Solution, USP) in 5 mL plastic DROP-TAINER® dispenser: NDC 0998-0623-05.


STORAGE: Store at 46° - 80°F (8° - 27°C).


Federal (USA) law prohibits dispensing without prescription.


Alcon®

OPHTHALMIC

ALCON (Puerto Rico) INC.

Humacao, Puerto Rico 00791 USA


Revised: June 1995 

Printed in USA

238382








STATROL 
neomycin sulfate and polymyxin b sulfate  solution










Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)0998-0623
Route of AdministrationOPHTHALMICDEA Schedule    
































INGREDIENTS
Name (Active Moiety)TypeStrength
neomycin sulfate (neomycin)Active3.5 MILLIGRAM  In 1 MILLILITER
polymyxin B sulfate (polymyxin B)Active16250 UNITS  In 1 MILLILITER
benzalkonium chlorideInactive 
hydroxypropyl methylcellulose 2910Inactive 
boric acidInactive 
sodium chlorideInactive 
hydrochloric acidInactive 
sodium hydroxideInactive 
waterInactive 


















Product Characteristics
Color    Score    
ShapeSize
FlavorImprint Code
Contains      










Packaging
#NDCPackage DescriptionMultilevel Packaging
10998-0623-055 mL (MILLILITER) In 1 BOTTLE, PLASTICNone






STATROL 
neomycin sulfate and polymyxin b sulfate  solution










Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)0065-0623
Route of AdministrationOPHTHALMICDEA Schedule    
































INGREDIENTS
Name (Active Moiety)TypeStrength
neomycin sulfate (neomycin)Active3.5 MILLIGRAM  In 1 MILLILITER
polymyxin B sulfate (polymyxin B)Active16250 UNITS  In 1 MILLILITER
benzalkonium chlorideInactive 
hydroxypropyl methylcellulose 2910Inactive 
boric acidInactive 
sodium chlorideInactive 
hydrochloric acidInactive 
sodium hydroxideInactive 
waterInactive 


















Product Characteristics
Color    Score    
ShapeSize
FlavorImprint Code
Contains      










Packaging
#NDCPackage DescriptionMultilevel Packaging
10065-0623-055 mL (MILLILITER) In 1 BOTTLE, PLASTICNone

Revised: 05/2006Alcon

More Statrol Ophthalmic Solution resources


  • Statrol Ophthalmic Solution Support Group
  • 0 Reviews · Be the first to review/rate this drug

No comments:

Post a Comment